Xtl Biopharmaceuticals (XTLB) Net Income towards Common Stockholders Growth (3y) (2012 - 2024)
Xtl Biopharmaceuticals (XTLB) Net Income towards Common Stockholders Growth (3y) (2012 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 45.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 91.31% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -202.20% |
| Sep 30, 2024 | 63.48% |
| Jun 30, 2024 | -37.72% |
| Mar 31, 2024 | 19.25% |
| Dec 31, 2023 | -8,628.52% |
| Sep 30, 2023 | 5,761.67% |
| Jun 30, 2023 | -7,040.05% |
| Dec 31, 2022 | -2.15% |
| Sep 30, 2022 | -4,698.68% |
| Jun 30, 2022 | -3,521.58% |
| Mar 31, 2022 | 1,980.08% |
| Dec 31, 2021 | 51.19% |
| Sep 30, 2021 | -7,462.44% |
| Mar 31, 2021 | 5,129.32% |
| Dec 31, 2020 | 95.43% |
| Sep 30, 2020 | -7.72% |
| Jun 30, 2020 | -30.66% |
| Dec 31, 2019 | -7,013.79% |
| Sep 30, 2019 | -25.99% |
| Jun 30, 2019 | -44.22% |